Agios Pharmaceuticals, Inc. (AGIO): A Bull Case Theory

We came across a bullish thesis on Agios Pharmaceuticals, Inc. on BioEquity Watch’s Substack. In this article, we will summarize the bulls’ thesis on AGIO. Agios Pharmaceuticals, Inc.'s share was trading at $27.80 as of January 15th. AGIO’s trailing and forward P/E were 3.54, respectively according to Yahoo Finance. I'll Play, Says Jim Cramer About Bristol-Myers (BMY) Photo by Myriam Zilles on Unsplash Agios Pharmaceuticals is a clinical-stage biotech company focused on cellular metabolism through oral, ...